Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leht 1 alates 32 tulemused
Dosimetry Using a CZT-camera Following LUTATHERA® Therapy
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
177Lu-DOTATATE has been proven to be an effective therapy for treatment of neuroendocrine tumors. Treatment with [177Lu]-DOTA-TATE consists of 4 cycles, with an infusion of 7.4 GBq (200mCi) every 8 weeks. An imaging protocol to study dosimetry throughout the cycles is essential to determine the
Lutetium-177-PSMA-I&T in Oligo-metastatic Hormone Sensitive Prostate Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against PSMA, which is overexpressed in prostate cancer cells. In the last few years, several Lutetium-177
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This is an open label, randomised, stratified, 2-Arm, multi-centre, phase 2 clinical trial recruiting 140 newly-diagnosed high-volume mHNPC patients at 11 Australian centres over a period of 18 months. Patients will be randomised to the experimental Arm (177Lu-PSMA followed by docetaxel) or
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Rationale: Prostate specific membrane antigen (PSMA) is a transmembrane protein, which is expressed on prostate cancers cells and other malignancies. Recently, several ligands have been developed that target PSMA. Linked to Gallium-68, this enables diagnostic 68Ga-PSMA-PET/CT scans. Linked to
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIMARY OBJECTIVE:
I. To evaluate the safety and to determine the recommended phase 2 dose (RP2D) of lutetium Lu 177 dotatate in combination with triapine.
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity. II. To determine the overall response rate (ORR) by Response Evaluation
PSMA-PET Imaging Before and After ADT in Advanced SDC Patients
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Rationale: Prostate specific membrane antigen (PSMA) is a transmembrane protein, which is expressed on prostate cancers cells and other malignancies. Recently, several ligands have been developed that target PSMA. Linked to Gallium-68, this enables diagnostic 68Ga-PSMA-PET/CT scans. Linked to
177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Prostate specific membrane antigen(PSMA) targeted therapy brings new hope to the patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we reported the safety and efficacy of 177 Lu -labeled PSMA ligand(PSMA-I＆T) in the treatment of mCRPC in Asianethics.
Prostate cancer is the
177Lu-PSMA-I&T Prior to Radical Prostatectomy for Locally Advanced Disease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIMARY OBJECTIVE:
I. Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by Ia. Computed tomography (CT) or Ib. Magnetic resonance imaging (MRI).
SECONDARY OBJECTIVES:
I. To estimate progression-free survival at 1-year. II. To correlate blood
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIMARY OBJECTIVES:
I. To estimate the efficacy of lutetium Lu 177 dotatate (LUTATHERA) treatment in patients with recurrent grade 1 meningioma as measured by 6-month progression-free survival (PFS) rate.
II. To estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 2 or 3
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIMARY OBJECTIVES:
1. To determine the recommended phase 2 dose and schedule of lutetium Lu 177-PSMA-617 (177Lu-PSMA-617) in combination with pembrolizumab in patients with metastatic castration-resistant prostate carcinoma (mCRPC). (Part A)
2. To determine the objective response rate by Response
Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Radioligand therapy (RLT) is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. In the last few years, several lutetium-177 (177Lu, β
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Rationale: The majority of neuroendocrine tumor (NET) patients present with metastases, most often including liver metastases. These patients have a poorer prognosis and lower quality of life.
Currently, intravenous administered somatostatin-bound radionuclides (177Lu-dotatate) have shown to improve
177Lu−J591 and 177Lu−PSMA−617 Combination for mCRPC
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This is an open−label, single−center Phase I dose−escalation study designed to determine the dose−limiting toxicity (DLT) and the maximum tolerated dose (MTD) of combination of 177Lu−J591 and 177Lu−PSMA−617 in a two−week dose−fractionation regimen. 177Lu−J591 will be given at a moderate dose
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
